CAP (CYCLOPHOSPHAMIDE, ADRIAMYCIN, CISPLATINUM) IN THE TREATMENT OF ADVANCED BREAST-CANCER

  • 1 January 1984
    • journal article
    • research article
    • Vol. 31  (4) , 431-435
Abstract
Fourteen patients with advanced carcinoma of the breast were treated with cyclophosphamide Adriamycin and cis platinum [CAP] combination therapy. An objective therapeutic response (partial remissions with a mean duration of 6.3 mo.) was achieved in 6 of 13 evaluated patients. This response was observed in soft tissue metastases. Nausea and vomiting were found to be the most frequent undesirable side effects in all patients and could not be avoided by administration of antiemetics metoclopramid. In 2 patients mild nephrotoxicity was found without any effects on further therapy. This study was considered promising; a definitive assessment of the CAP regimen is expected to come from a randomized study which started in the CMEA countries in 1983.